Abstract:OBJECTIVE:(Background): Alzheimer's disease (AD), clinically characterized by the progressive neurodegenerative condition and cognitive impairment, is one of the main causes of disability in elder people worldwide. Recently, several animal studies indicated that the 'gut-brain' axis might contribute to the amyloid deposition of AD. However, data about gut dysbiosis in human AD remains scarce in the literature, especially including the whole process of AD. In this prospective and cross-sectional study, we aimed at identifying differences in microbiome between patients with AD (Pre-onset stage amnestic mild cognitive impairment, aMCI; and AD) and the normal cognition healthy controls (HC). Additionally, the potential association between IM and clinical characteristics of AD was evaluated.METHODS:A total of 97 subjects (33 AD, 32 aMCI, and 32 HC) were recruited in the study. The composition of gut bacterial communities was determined by 16S ribosomal RNA Miseq sequencing. In addition, Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) was used to predict function shift of intestinal microbiota. The Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA) or Clinical Dementia Rating (CDR) scores were used to evaluate the severity of cognitive impairment in patients.RESULTS:The fecal microbial diversity was decreased in AD patients compared with aMCI patients and HC. And the microbial composition was distinct among aMCI, AD and healthy control groups. Among bacterial taxa, the proportion of phylum Firmicutes was significantly reduced (P = 0.008), whereas Proteobacteria (P = 0.024) was highly enriched in the AD compared with HC. In addition, similar alterations were observed at the order, class and family levels of these two phyla. And Gammaproteobacteria, Enterobacteriales and Enterobacteriaceae showed a progressive enriched prevalence from HC to aMCI and AD patients. Further, a significant correlation was observed between the clinical severity scores of AD patients and the abundance of altered microbiomes. Moreover, the KEGG results showed the increased modules related to glycan biosynthesis and metabolism in AD and aMCI patients and decreased pathways related to immune system in AD patients. Importantly, the discriminating models based on predominant microbiota could effectively distinguish aMCI and AD from HC (AUC = 0.890, 0.940, respectively), and also AD from aMCI (AUC = 0.925). Notably, the models based on the abundance of family Enterobacteriaceae could distinguish AD from both aMCI (AUC = 0.688) and HC (AUC = 0.698).CONCLUSIONS:Distinct microbial communities, especially enriched Enterobacteriaceae, were associated with patients with AD when compared with predementia stage aMCI and healthy subjects. These novel findings will give new clues to understand the disease and provide new therapeutic target for intervention or a marker for this disease.

Dynamic Changes in the Levels of Amyloid-β42 Species in the Brain and Periphery of APP/PS1 Mice and Their Significance for Alzheimer’s Disease

Gut-derived Β-Amyloid: Likely a Centerpiece of the Gut–brain Axis Contributing to Alzheimer’s Pathogenesis

Analysis of Serum Β-Amyloid Peptides, Α2-Macroglobulin, Complement Factor H, and Clusterin Levels in APP/PS1 Transgenic Mice During Progression of Alzheimer's Disease.

Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice.

Study of Regional Metabolites by Quantitative Proton MR Spectroscopy in APP/PS1 Double Transgenic Alzheimer Disease Mice

Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease

Altered Microbiomes Distinguish Alzheimer's Disease from Amnestic Mild Cognitive Impairment and Health in a Chinese Cohort.

Alzheimer’s Disease Histological and Behavioral Manifestations in Transgenic Mice Correlate with Specific Gut Microbiome State

Progressive Spatial Memory Impairment, Brain Amyloid Deposition And Changes In Serum Amyloid Levels As A Function Of Age In Appswe/Ps1de9 Mice

Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid-β Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimer's Disease Pathology.

Longitudinal Assessment of Peripheral Organ Metabolism and the Gut Microbiota in an APP/PS1 Transgenic Mouse Model of Alzheimer's Disease

Multiple Inflammatory Profiles of Microglia and Altered Neuroimages in APP/PS1 Transgenic AD Mice.

Untargeted Lipidomics Reveals Progression of Early Alzheimer’s Disease in APP/PS1 Transgenic Mice

Identification of Microbiota Within Aβ Plaque in APP/PS1 Transgenic Mouse

Proteomic Analysis of Protein Expression Throughout Disease Progression in a Mouse Model of Alzheimer’s Disease

Soluble Β-Amyloid Impaired the GABA Inhibition by Mediating KCC2 in Early APP/PS1 Mice.

Analysis the alteration of systemic inflammation in old and young APP/PS1 mouse

Fecal 16S rRNA sequencing and multi-compartment metabolomics revealed gut microbiota and metabolites interactions in APP/PS1 mice

Proteomic profiles of the early mitochondrial changes in APP/PS1 and ApoE4 transgenic mice models of Alzheimer disease.

Alterations of fatty acid composition and metabolism in APP/PS1 transgenic mice

iTRAQ-based Proteomic Analysis of APPSw,Ind Mice Provides Insights into the Early Changes in Alzheimer's Disease.